# Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints

> **NCT06616571** · PHASE4 · RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 336 (estimated)

## Conditions studied

- Chemotherapy-Induced Febrile Neutropenia

## Interventions

- **DRUG:** QL0605(PEG-rhG-CSF)
- **DRUG:** QL0605(PEG-rhG-CSF)

## Key facts

- **NCT ID:** NCT06616571
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-19
- **Primary completion:** 2025-12-30
- **Final completion:** 2025-12-30
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06616571

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06616571, "Compare the Efficacy and Safety of QL0605 Injections at Different Timepoints". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06616571. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*